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Fusion peptideSevere acute respiratory syndrome-associated coronavirus (SARS-CoV) poses a serious public health hazard. The
S2 subunit of the S glycoprotein of SARS-CoV carries out fusion between the virus and the host cells. However, the
exact mechanism of the cell fusion process is not well understood. Current model suggests that a conformational
transition, upon receptor recognition, of the two heptad core regions of S2 may expose the hydrophobic
fusogenic peptide or fusion peptide formembrane insertion. Three regions of the S2 subunit have been proposed
to be involved in cell–cell fusion. The N-terminal fusion peptide (FP, residues 770–788), an internal fusion pep-
tide (IFP, residues 873–888) and the pre-transmembrane region (PTM, residues 1185–1202) demonstrated
interactions with model lipid membranes and potentially involved in the fusion process. Here, we have deter-
mined atomic resolution structures of these three peptides in DPC detergent micelles by solution NMR. FP
assumes α-helical conformation with signiﬁcant distortion at the central Gly residues; enabling a close packing
among sidechains of aromatic residues including W, Y and F. The 3-D structure of PMT is characterized by a
helix–loop–helix with extensive aromatic interactions within the helices. IFP adopts a rather straight α-helical
conformation deﬁned by packing among sidechains of aromatic and aliphatic residues. Paramagnetic spin labeled
NMR has demonstrated surface localization of PMT whereas FP and IFP inserted into the micelles. Collectively,
data presented in this study will aid in understanding fusion mechanism of SARS-CoV.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Membrane fusion is an important step for a successful infection of
the enveloped viruses causing the transfer of viral genetic materials
into the host cell. The energy barrier of membrane fusion is overcome
by a coordinated process mediated by specialized viral fusion proteins
[1–4]. Most fusion proteins are produced as precursor proteins which
are often cleaved by host cell proteases, yielding a metastable complex
consisted of a receptor binding subunit and a membrane fusion subunit
[1–4]. Upon binding to the cell surface receptor or being in the acidic
environment of endosome, fusion proteins are activated following a
dramatic conformational transition which essentially sets free a buried
hydrophobic fusion peptide from the protein core [1,2,5–9]. The fusion
peptide, once exposed, inserts into the outer-leaﬂet of the lipid bilayer,
initiating the cell fusion process [5–9].While, a part of the fusion protein
undergoes an irreversible refolding to a stable conformation thatdrome-associated coronavirus
ce; NOESY, nuclear Overhauser
DPC, dodecyl phosphocholine
e, 637551. Fax:+65 6791 3856.releases free energy to overcome the membrane fusion barrier [5–9].
Consequently, a thorough understanding of the molecular basis of the
fusion mechanism has been deemed vital not only for the virus life
cycle but also for the rational design of potential therapeutics [10–14].
Therefore, atomic-resolution structures of fusion proteins are essential
for obtainingmechanistic insights of membrane fusion process. Toward
this, 3-D structures, using X-ray crystallography, of a number of fusion
proteins, full length or fragment, are reported in their pre fusion or
post fusion states [2,4,15–19]. As such, these atomic-resolution struc-
tures have provided important molecular insights for membrane fusion
and drug discovery. However, atomic resolution structures of the full-
length fusion proteins in complex with lipid membrane remain a chal-
lenging task. In order to infermembrane interactions of fusion processes,
fusion peptides are investigated for structural and functional characteri-
zation in lipid or membrane mimetic environments [20–29].
During 2002–2003, SARS-CoV emerged as a global health riskwhich
was speared over 29 countries infecting approximately 9000 people
with 774 deaths worldwide [30–32]. More recently, a new coronavirus,
designated hCoV-EMC or Middle East Respiratory Syndrome coronavi-
rus (MERS-CoV), has been identiﬁed in humans inMiddle Eastern coun-
tries and England causing death of several hundred of the infected
people [33–36]. Coronaviruses, including SARS-CoV and MERS-CoV,
Fig. 1. Spike glycoprotein of SARS-CoV is composed of twodomains S1 and S2 separated by a protease cleavage site. TheN-terminal domain has a signal peptide (SP) and a transmembrane
domain (TM) is present at the C-terminus. Other regions are receptor binding domain (RBD), two heptad repeat (HR1 and HR2) sequences and putative fusion peptides named as fusion
peptide (FP), internal fusion peptide (IFP) and pre transmembrane domain (PTM).
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ed to the respiratory, hepatic and gastric systems. Due to its recurrent
emergence, rapid and facile transmission, and highmortality, it is essen-
tial to gain a better understanding of the pathogenesis of this virus toFig. 2. Fingerprint regions of 1H–1H 2-D NOESY spectra of SARS-CoV fusion peptides showing se
DPC micelles.develop antiviral drugs and vaccines for the cure and prevention of
SARS and MERS [37–40].
The large positive-stranded RNA genome of SARS-CoV enters into the
host through cell fusionmediated by the viral spike (S) glycoprotein [41].quence speciﬁc resonance assignments of FP (panel A), IFP (panel B) and PTM (panel C) in
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whereas the S2 subunit primarily involves fusion between virus and
target cell membrane [42–44]. The fusion protein or the S2 subunit
of SARS-CoV has been designated to the class I type fusion protein
[45,46]. As a member of this class, the S2 subunit of S glycoprotein
contains a pair of heptad repeats, HR1 and HR2 and a TM region at the
C-terminus. Based on peptides corresponding to HR1 and HR2 it has
been demonstrated that HR1 and HR2 forms antiparallel oligomeric
complex [45–48]. Atomic-resolution structures of HR1 andHR2 complex
showed formation of a six helix bundle or trimer-of-hairpins structure, a
conserved feature of the class I fusion proteins [49–52]. Three separate
regions of the S2 domain of S protein of SARS-CoV have been identiﬁed
asmember active peptides, named as fusion peptide (FP), internal fusion
peptide (IFP) and a pre-transmembrane (PTM) domain near the C-
terminal TM (Fig. 1) (53–56). Vesicle fusions, membrane interactions
and biophysical characterization have been carried out for these peptides
FP, IFP and PTM, revealing their fusogenic ability, high-afﬁnity to parti-
tion into lipid membranes and membrane destabilization [53–59].
More recently, yet another peptide segment, residues 798 to 815, of
S protein has been identiﬁed as a potential fusion peptide [60].
It has been proposed that the membrane fusion in SARS-CoV may
involve the HR1, HR2 and these membrane active peptides to form the
fusion pore in membrane (53, 56, 59). Notably, synthetic peptides
corresponding to these regions demonstrated inhibition of SARS-CoV
infection, presumably destabilizing cell fusion process [61]. Atomic res-
olution structure of any of these fusion peptides of SARS-CoV is yet to be
reported. In order to gain insights into membrane fusion mechanism,
here we have determined 3-D structures of the three fusion peptides
of SARS-CoV in DPC detergent micelles. Our current results would
help in better understating of the virus and host cell fusions and may
aid in antiviral drug development.Fig. 3. Sections of 1H–1H 2-D NOESY spectra of FP (panel A), IFP (panel B) and PTM (panel C) sh
with up-ﬁeld shifted aliphatic resonances (4.5–0.8 ppm).2. Materials and methods
2.1. Peptides and chemicals
Synthetic peptides were purchased commercially from GL-Biochem
(China)with purity of N98%.Deuterated compounds (DPC-d38 andD2O)
and 4, 4-dimethyl-4-silapentane-1-sulfonic acid (DSS) were obtained
from Cambridge Isotope Laboratories, Inc. (Massachusetts, USA). Para-
magnetic lipids, 5-DSA and 16-DSA (doxyl stearic acid) were purchased
from Sigma-Aldrich (St. Louis, MO, USA).
2.2. NMR spectroscopy and data processing
NMR spectra were acquired in a Bruker AVANCE II 600 MHz
spectrometer equipped with a cryoprobe. Lyophilized peptide samples
(0.5 mM) were dissolved in 90% H2O/10%D2O, pH 4.7, containing
125 mM perdeuterated DPC. Typically, two-dimensional (2-D) 1H–1H
TOCSY (mixing time 80 ms with 32 scans) and NOESY (mixing time
200 ms with 88 scans) spectra were acquired using spectral width of
13 ppm with 2 K × 512 complex points and the States-TPPI for quadra-
ture detection at the t1 dimension. All NMR experiments were per-
formed at a temperature of 315 K. Water signal was suppressed using
WATERGATE. Natural abundance 13C–1H HSQC spectra (for 13Cα chem-
ical shifts)were acquired bydissolving lyophilized peptides (0.5mM) in
D2O containing 125mMperdeuterated DPC. HSQC spectra were obtain-
ed using spectral width of 12 and 80 ppm for 1H and 13C, respectively,
with 300 scans. Chemical shifts were referenced with respect to DSS
as an internal reference. For probing localization and insertion of pep-
tides in DPC micelles, PRE (paramagnetic relaxation enhancement)
studies were conducted by acquiring 2-D TOCSY spectra either in
the absence or in the presence of 1 mM of 5-DSA and 16-DSA. Stockowing NOEs contacts of low-ﬁeld shifted aromatic ring proton resonances (6.5–7.5 ppm)
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intensities of the CαH/NH cross-peaks of amino acids in TOCSY spectra
were estimated before and after addition of the paramagnetic probes
and the % attenuation in intensity for both 5-DSA and 16-DSA were
calculated. NMR data were processed using TopSpin 3.0 (Bruker).
After zero ﬁlling along the t1 dimension, 2 K (t2) × 1 K (t1) data matri-
ces were obtained. Spectral analysis and peak picking were done using
SPARKY 3.113.
2.3. Structure calculations
The assigned NOE peaks were classiﬁed as strong, medium or weak
and translated to an upper bound distance restraints: 2.8, 3.5 and 5.0 Ǻ,
respectively. Backbone dihedral angles ϕ and ψ, were calculated using
Preditor using 1Hα and 13Cα chemical shifts [62] and used for angular
constraints. The DPC-bound structures fusion peptides were calculatedFig. 4. Bar diagram summarizing number and types of NOEs for FP (panel A), IFP (panel B)
and PTM (panel C). Intra-residue, sequential and medium range NOEs are marked as
white, light gray and dark bars, respectively.using CYANA (version 2.1) [63]. The structure calculation was done in
a stepwise manner to get the ﬁnal ensemble with low RMSD and target
function.
3. Results
3.1. NMR analyses of SARS-CoV of FP, IFP and PTM peptides
High-quality NMR spectra of SARS fusion peptides were obtained
in solution containing DPC micelles. Sequence-speciﬁc resonance
assignments of fusion peptides were achieved by analyses of two-
dimensional 1H–1H TOCSY and NOESY spectra [64]. Fig. 2 shows
sequential connectivity in the NOESY spectra of FP (panel A), IFP
(panel B) and PTM (panel C). As can be seen, most of the resonances
of FP, IFP and PTM are unambiguously identiﬁed. Peptide–micelle
complexes were found to be stable over the period of time with no
new resonances or line-width changes observed, suggesting absence
of any potential miceller fusions by these peptides. Analyses of NOESY
spectra reveal backbone/backbone backbone/sidechain and sidechain/
sidechain NOE contacts for these fusion peptides. FP, IFP and PTM pep-
tides are rich in aromatic amino acids; a number of NOEs could be iden-
tiﬁed involving aromatic ring protons with the backbone and sidechain
protons of aliphatic residues (Fig. 3). Fig. 4 summarizes NOE contacts
detected for FP (panel A), IFP (panel B) and PTM (panel C) peptides.
NOE connectivities are characterized by sequential and medium range
for all three fusion peptides (Fig. 4). Noticeably, aromatic residues of
FP, IFP and PTM have delineated more number of NOE contacts com-
pared to other residues. Further, residues Y9 and F10 of FP, residues
F8, Y14 and F15 and residues Y4 and Y7 of PTM exhibited over 20, 24
and 30 NOEs, respectively (Fig. 4). The amino acid sequence of PTM
fusion peptide contains as many as six aromatic residues; most of
these residues are found to be involved in a number of NOE contacts
(Fig. 4C). Taken together, the large number of NOE contacts observed
for FP, IFP and PTM peptides indicate that these fusion peptides assume
well-deﬁned conformations in DPC micelles.
3.2. Atomic-resolution structures of FP, IFP and PTM peptides
3-D structures of FP, IFP and PTM peptide are determined using
CYANA based on NOE-driven distance and backbone dihedral angle
(ϕ,ψ) constrains. A total of 153, 148 and 182 distance constrains are
used for FP, IFP and PTM, respectively, to obtain the structural ensem-
bles (Table 1). Fig. 5A shows superposition of twenty lowest energy
structures of FP. The backbone and all heavy atoms RMSD values from
the mean structure of FP are estimated to be 0.38 Å and 0.98 Å, respec-
tively (Table 1). As can be seen, backbone atoms of residues T4-L19 and
also sidechains of residues Y9, F10, F13, F15 L7, I18 and L19 demonstrateTable 1
Structural statistics of twenty lowest energy structures of FP, IFP and PTM in DPCmicelles.
Distance constraints FP IFP PTM
Intra residue (i = j) 89 86 80
Sequential (i–j = 1) 44 37 56
Medium range [1 b |i–j| ≤ 4] 20 25 46
Total 153 148 182
Angle constraints
ϕ, ψ constraints 34 28 30
Deviation from mean structure
All backbone atoms 0.38 0.43 0.15
All heavy atoms 0.98 0.82 0.80
aRamachandran plot for the mean structure
% residues in the most favored region 92.9 100 84.6
% residues in the additionally allowed region 7.1 0.0 15.4
% residues in the generously allowed region 0.0 0.0 0.0
% residues in the disallowed region 0.0 0.0 0.0
a Calculated using Procheck.
Fig. 5. (A) Backbone superposition of twenty lowest energy structures of FP in the presence of DPC micelles. (B) A representative structure of the micelle bound FP showing backbone
folding as ribbon and sidechain disposition as stick. (C) A surface representation of FP showing localization of polar amino acids (blue color) and hydrophobic residues (yellow).
Figures were generated using molecular visualization software Molmol and PyMol.
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posed in the structural ensemble of FP (Fig. 5A). These observations in-
dicate that a rather rigid structure for most of the residues in T4–L19
segment of FP, although residues at the N-terminus of FP, M1–W2–L3,
lacks well-deﬁned conformations. FP assumes a ‘V-shaped’ bend helical
conformations for residues P5–I18, while N-terminal residues W2–T4
are found to be largely non-helical or in extended conformations
(Fig. 5B). The V-shaped helical conformation of FP appears to beFig. 6. (A) Backbone superposition of 20 lowest energy structures of IFP in DPC micelles. (B) A
sidechain disposition as stick. (C) A surface representation of IFP showing localization of polar a
molecular visualization softwares Molmol and PyMol.resulting at the centrally located two Gly residues G11–G12 including
the residue F10 (Fig. 5B). There are two hydrophobic patches in the
bend helical conformations of FP consisted of the sidechains of residues
L7, Y9, F10, and F13 and the sidechains of residues F15, I18, and L19
(Fig. 5C). Sidechains of residues T6, N14, and Q17 are positioned along
the same face of the bend helix of FP, indicating a potential polar surface
(Fig. 5C). Fig. 6A shows twenty lowest energy superposed structure of
the IFP. The backbone and all heavy atom RMSDs from the meanrepresentative structure of the micelle bound IFP showing backbone folding as ribbon and
mino acids (blue color) and hydrophobic residues (yellow). Figures were generated using
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close superposition can be seen for all residues, except for the ﬁrst
three N-terminal residues G1–A2–A3 (Fig. 6A). The IFP adopts a canon-
ical α-helix encompassing residues L4–R15 (Fig. 6B). One face of the
helix is predominantly hydrophobic containing sidechains of residues
I6, A9, M10, A13 and F16, whereas the opposite surface of the helix dis-
plays sidechains of non-polar and also polar residues (Fig. 6B). In partic-
ular, non-polar packing interactionsmay be sustained by the sidechains
of residues L4, F8 and M12 (Fig. 6B). By contrast, a close proximity of
sidechains of residues Q11, Y14, and R15 may render polar interactions
in the helix of IFP (Fig. 6B). Fig. 7A represents superposition of twenty
lowest energy structures of the PTM peptide. The backbone and all
heavy atoms RMSD values from the mean structure are restricted to
0.15 Å and 0.80 Å, respectively (Table 1). The primary structure of
PTM is rich in aromatic amino acids including one Phe, three Tyr and
three Trp residues. The sidechains of these aromatic residues are well
deﬁned, except for the terminal residues W15 and F18 (Fig. 7A). TheFig. 7. (A) Backbone superposition of 20 lowest energy structures of PTM inDPCmicelles. (B) A r
sidechain disposition as stick. (C) A surface representation of PTM showing localization of
Figures were generated using molecular visualization softwares Molmol and PyMol.PTM peptide assumes a helix–loop–helix type conformation, whereby
residues at the N-terminal K3–Y7 and residues at the N-terminal
W10–W15 adopt helical conformations (Fig. 7B). These two short heli-
ces are connected by a loop comprised of residues I8 and K9 (Fig. 7B).
The C-terminal helix displays an extended hydrophobic patch made of
by sidechains of residues W10, V14 and F18 at one face of the helix
and residues I8, W12, L16 and W15 located at the opposite face of the
helix (Fig. 7C). The N-terminal helix and the loop of PTM structure are
largely polar containing basic residues K3 and K9, negatively charged,
E5 and polar residues. Sidechains of the residue E5 and the residue K9
are found to be in a close proximity ~6 Å, indicating potential salt bridge
and/or hydrogen bond interactions (Fig. 7C).
3.3. Localization of FP, IFP and PTM peptides in DPC micelles
Paramagnetic relaxation enhancement (PRE) NMR studies, by spin
labeled doxyl lipids, have been utilized to obtain micelle associationepresentative structure of themicelle bound PTM showing backbone folding as ribbon and
polar amino acids (blue and red color) and hydrophobic residues (yellow and green).
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TOCSY spectra of the three peptideswere acquired either in the absence
or in the presence of 1 mM spin labeled lipids, 5-doxyl-stearic acid
(5-DSA) and 16-doxyl-stearic acid (16-DSA). Fig. 8 shows %attenuation
of αH/NH cross-peak intensity, caused by the PRE probes, of TCOSY
spectra for FP (panel A), IFP (panel B) and PTM (panel C). As can be
seen, most of residues of three fusion peptides have experienced
PRE mediated signal attenuation, indicating localization into micelles.
However, three fusion peptides delineate differential signal attenuationFig. 8. Bar diagrams showing the % attenuation of CαH/NH cross peaks upon additions of parama
attenuation cannot be obtained for few residues; these are indicated by a ﬁlled circle.in 5-DSA and 16-DSA. For example, residues of IFP appear to show
a similar % of attenuation in 5-DSA and 16-DSA (Fig. 8B), whereas a sig-
niﬁcantly large number of residues of PTM are found to be perturbed by
5-DSA compared to 16-DSA probe (Fig. 8C). By contrast, residues of FP
exhibit disparate signal attenuation in 5-DSA and 16-DSA (Fig. 8A).
These observations indicate that the three fusion peptides might
encompass a different depth of insertion into DPC micelles. It may be
noted that a preferential signal attenuation detected in 16-DSA in com-
parison to that of 5-DSA is indicative of a deeper insertion of the residuegnetic probes, 5-DSA and 16-DSA, for FP (panel A), IFP (panel B) and PTM (panel C). Signal
Fig. 9. A hypothetical model of membrane fusion between SARS-CoV and host cells show-
ing involvement of the three putative fusion peptides, FP, IFP and PTM. Upon activation by
receptor binding of the S1 domain, the FP (blue color) and IFP (red color) of the S2 domain
of the fusion protein insert into host cells causing folding backof theHR1 (green color) and
HR2 (yellow color) into six helix bundle. The aromatic residue rich PTMdomain (magenta
color) and the TM domain residing on the viral membrane provide a contiguous track of
hydrophobic helical structures with HR domains and fusion peptides. Such an arrange-
ment may facilitate the mixing of lipid molecules between the two membranes leading
to the fusion of the viral and host cells.
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micelle head group in case of higher attenuation caused by 5-DSA probe
[65,66]. As can be seen, residues W2, K3 and K8 of FP demonstrate
~100% signal attenuation in 16-DSA, 5-DSA has caused lower signal
attenuation for these residues, indicating a deep penetration of these
residues of the FP into the micelle core (Fig. 8A). Residues L7, F10 and
F15 also delineate 100% signal attenuation in the presence of both the
doxyl probes (Fig. 8A). Other residues, T4, T6, T9, G11, F13, N14 and
S16 show similar degree of perturbation in both probes indicating that
these residues of FP are likely to be located toward the center of the
micelle with a more surface penetration. The C-terminal residues Q17,
I18 L19 and residue G12 exhibit lower perturbation, compared to
other residues, in both doxyl probes (Fig. 8A). Thus, these residues
may reside closer to the water/head group surface of the micelle. In
particular, PRE data suggest that the unstructured segment of the
N-terminus and a signiﬁcant region, except the bend residue G12 and
C-terminal end residues, of the helical structure of FP are embedded
into the DCP micelle. In case of IFP, PRE studies reveal a nearly 100%
signal attenuation, caused by 16-DSA, for almost all the residues, except
for A2 (Fig. 8B). 5-DSA has also produced ≥80% signal attenuation for
these residues of IFP (Fig. 8B). These observations indicate that the
most of the residues of IFP helical structure are positioned toward the
micelle center. In the case of PTM peptide, an overwhelming number
of residues including K3, Y4, E5, Y7, I8, W12, V14, G17 and F18 turns
out to be more perturbed by 5-DSA in comparison to 16-DSA probe
(Fig. 8C). Whereas, limited signal attenuation can be observed for resi-
dues G2, Q6 and W10. Therefore, the helix–loop–helix structure of
PTM is largely occupying water/micelle interfacial region. Collectively,
PRE studies of the three fusion peptides of SARS-CoV delineate that all
three peptides, FP, IFP and PTM assume a parallel orientation in the
DPC micelles, whereby, FP and IFP may have a deeper micelle penetra-
tion whereas PTM peptide is predominantly surface localized.
4. Discussion
Virus–host membrane fusion mechanism involves sequence of dif-
ferent steps including apposition of membranes, formation of a stalk
resulting from hemifusion of the outer leaﬂets, the generation of a
fusion pore through amalgamation of both bilayers at the stalk point,
and lastly, enlargement of the fusion pore and mixing [1–4]. Inves-
tigation of SARS-CoV fusion mechanism would contribute to the
understating of virus pathology and designing drugs and vaccines. The
S protein of SARS-CoV is known to be causing the fusion between the
virion envelop and cellular membrane [41–44]. As a prototype of type
I fusion protein, the HR1 and HR2 regions of the S protein of SARS-CoV
form trimers of coiled-coil six helix bundle structure [49–52]. Analogous
to the other class I fusion proteins, several trimers of the S protein are
involved in membrane juxtaposition, destabilization and fusion pore
formation. In addition, a large number of studies have pointed out that
multiple regions in the fusion proteins, both in type I and type II are
decisive in the membrane fusion process [6,67,68]. These segments of
fusion proteins bind and destabilize lipid membrane toward the fusion
of biologicalmembranes. Three regions, FP, IFP and PTM, of the S protein
of SARS-CoV have been identiﬁed as plausible membrane fusogenic
element (Fig. 1). Synthetic peptides corresponding to FP, IFP and PTM
delineate binding to model membranes or liposomes, lipid mixing,
destabilization of lipid bilayers and characteristics of typical fusion
peptides [53–60]. However, conformational characteristics of these
fusogenic peptides of SARS-CoV were investigated only by CD and FT-
IR assessing global conformational preferences inmembranemimicking
environments. The current study elucidates the ﬁrst atomic resolution
structures of FP, IFP and PTM peptide in solution containing DPC deter-
gent. It may be noted that 3-D structures of a number of fusion peptides
from type I and type II fusion proteins have been obtained in solutions of
micelles either DPC or SDS, mimicking membrane environment [23,26,
28,29,69–72]. Zwitterionic DPCmicelles perhaps act as a bettermimic ofmammalian cell membrane and support tertiary and quaternary pack-
ing in short peptides [73,74]. Our results demonstrate that the three
fusion active peptides of SARS-CoV fold into predominantly helical con-
formations also containing residues with extended or loop like confor-
mations in DPC micelles. In particular, the 3-D structure of FP has been
deﬁned by a V-shaped kinked helical structure encompassing residues
P5–I18. The N-terminal segment of FP consisting of residues W2–K3–
T4 is found to be more ﬂexible. The kinked structure of FP appears to
be rather compact and sustained by potential inter-sidechain packing.
The surface of the FP structure contains a narrow polar region and ex-
tended hydrophobic sections. PRE studies, using spin labeled doxyl
lipids, indicate that the residues, e.g. L7, Y9, F10, and F15 at the hydro-
phobic patches along with structurally ﬂexible residues W2-K3 of the
N-terminal of FP are inserted into DPCmicelles whereas C-terminal res-
idues are plausibly located at the micelle surface. Previously, intrinsic
tryptophan ﬂuorescence studies of FP have also demonstrated insertion
of residueW2 inmodel membranes with restricted solvent accessibility
[53,58]. Notably, the fusion peptide of inﬂuenza virus has been found to
adopt similar V-shaped conformations in micelles and in lipid bilayers
[25,75].
Most of the residues of IFP, except for the two N-terminal residues,
assume helical structure without any bend or kink. The IFP helix is
highly hydrophobic, compared to FP and PTM helices, and most of the
residues of IFP appear to be mostly inserted into the non-polar region
of the DPC micelles. Previous biophysical studies of IFP in model mem-
branes demonstrated incorporation of IFP into the non-polar core and
disruption of the acyl chain packing of the lipid bilayers [55]. Taken
together, the long hydrophobic patch delineated in the helical structure
of IFP may be responsible for such higher portioning of IFP into lipidic
environment and perturbation of membrane structures. The aromatic
rich PTM peptide of SARS-CoV adopts a helix–loop–helix structure in
DPC micelles. The C-terminal helix of PTM is non-polar and contains
aromatic packing interactions between residuesW12 andW15, where-
as the short N-terminal helix is characterized by polar and ionic resi-
dues. PRE studies indicate that the PTM helix is more surface localized
in comparison to FP and IFP. It is noteworthy that a straight helical
structure of a 19-residue long PTM peptide of HIV fusion protein has
been determined in DPC micelle solution [76]. The aromatic rich region
close to the transmembrane domain is a conserved feature among type I
fusion proteins and potentially involved in membrane fusion [56].
Virus–hostmembrane fusionmechanism is a complex process whereby
multiple regions of the fusion protein might be involved in membrane
interactions [5,20,22]. Some of these regions of the fusion protein can
cause membrane fusion and other segments may be required for the
membrane anchoring function.
729M. Mahajan, S. Bhattacharjya / Biochimica et Biophysica Acta 1848 (2015) 721–730Our results can be used to further reﬁne the current model of mem-
brane fusion of SARS-CoV (Fig. 9). Whereby, helical structures of FP, IFP
and PTM, alongwith the TM anchor, insert into themembrane andmay
align with the six-helix bundle structure of HR1 and HR2 resulting in
possible juxtapositioning of the host and viral membranes. The high
hydrophobicity of the fusion active structure made of by these helices
of the fusion protein would cause membrane mixing and eventually
formation of the fusion pore. In addition, the emergence of highly infec-
tious coronavirus termed MERS has prompted discovery of anti-SARS
drugs. The fusion peptides of SARS-CoV have been found to be active
against viral infection possibly due to their interactions with mem-
branes [10,60]. Thus, 3-D structures of fusion peptides and membrane
fusionmechanismmay be further utilized to develop drug against SARS.
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